Actelion Share Price

Stocks

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/17/22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/17/18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/17/20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/17/18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/17/05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/17/31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/17/23	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/20/06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/17/30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/17/16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/17/16	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/18/29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/18/29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/18/22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/17/30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	+0.99%	-	-	0
WUXI APPTEC CO., LTD.	-4.10%	-8.35%	+38.48%	+66.99%	6.62TCr
ARGENX SE	-0.41%	+4.99%	+7.61%	+72.82%	5.52TCr
LONZA GROUP AG	+0.74%	+7.31%	+12.50%	+88.71%	5.28TCr
IQVIA HOLDINGS INC.	+0.61%	+6.22%	+27.28%	+50.97%	4.55TCr
BEONE MEDICINES AG	-1.08%	+8.76%	+21.07%	+131.38%	4.39TCr
REVOLUTION MEDICINES, INC.	-3.39%	-3.01%	+250.89%	+571.04%	4.16TCr
CELLTRION, INC.	-1.67%	+8.06%	+14.17%	+56.67%	3.4TCr
WUXI BIOLOGICS (CAYMAN) INC.	-8.38%	-9.01%	+25.65%	-1.82%	2.58TCr
GENMAB A/S	+1.30%	+6.97%	+38.37%	+28.59%	2.35TCr
Average	-1.64%	+3.43%	+48.45%	+118.37%	4.32TCr
Weighted average by Cap.	-1.69%	+3.43%	+47.06%	+122.37%